Renaissance Capital logo

Genetic defect biotech Audentes files for a $86 million IPO

January 4, 2016
BOLD

Audentes Therapeutics, which is developing gene therapy treatments for X-Linked Myotubular Myopathy (XLMTM), filed on Monday with the SEC to raise up to $86 million in an initial public offering.

The San Francisco, CA-based company, which was founded in 2012, plans to list on the Nasdaq under the symbol BOLD. Audentes Therapeutics filed confidentially on 11/6/2015. BofA Merrill Lynch, Cowen & Company and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.